Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

WT1 monitoring in core binding factor AML: comparison with specific chimeric products.

Leukemia research - 1 Dec 2009

Lasa Adriana, Carricondo Maite, Estivill Camino, Bussaglia Elena, Gich Ignasi, Brunet Salut, Aventin Anna, Sierra Jorge, Nomdedéu Josep F

Abstract excerpt

Minimal residual disease may help to establish clinical decisions in patients with AML. WT1 offers the possibility to analyze those cases without currently known underlying genetic abnormalities. To compare the value of chimeric specific quantitative PCR with WT1 PCR in CBF acute leukemia, 445 samples from 96 AML (49 AML1-ETO+ and 47 CBFB-MYH11+) cases were included in the study. For each sample AML1-ETO or...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Case-Control Studies
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genes, Wilms Tumor

Share to Leukemia, Myeloid, Acute

Share to Monitoring, Physiologic

Share to Recombinant Fusion Proteins

Share to Young Adult

Source

Identifiers

PMID: 19427034
DOI: 10.1016/j.leukres.2009.03.046

Genes

CBFB
MYH11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

WT1 monitoring in core binding factor AML: comparison with specific chimeric products.PMID 19427034Read ↗

Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter studySemantic proximity Read ↗

WT1 as a Universal Marker for Minimal Residual Disease Detection and Quantification in Myeloid Leukemias and in Myelodysplastic SyndromeSemantic proximity Read ↗

Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometrySemantic proximity Read ↗

RNA sequencing as an alternative tool for detecting measurable residual disease in core-binding factor acute myeloid leukemia.Semantic proximity Read ↗

WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.Semantic proximity Read ↗

High Levels of Wilms' Tumor Gene (wt1) mRNA in Acute Myeloid Leukemias Are Associated With a Worse Long-Term OutcomeSemantic proximity Read ↗

Involvement of a common progenitor cell in core binding factor acute myeloid leukaemia associated with mastocytosis.Semantic proximity Read ↗

Fluorescent 5′‐exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemiasSemantic proximity Read ↗

Prognostic significance of quantitative analysis of <i>WT1</i> gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemiaSemantic proximity Read ↗

Detection and quantification of TEL/AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia.Semantic proximity Read ↗

[The significance of quantification of MDR1 and WT1 gene expression in acute myeloid leukemia].Semantic proximity Read ↗

Persistent altered fusion transcript splicing identifies <i>RUNX1‐RUNX1T1</i>+ AML patients likely to relapseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.